GENERAL CONSIDERATIONS FOR CLINICAL STUDIES E8(R1), ICH Consensus Guideline
Clinical studies of medicinal products are conducted to provide information that can ultimately improve access to safe and effective products with meaningful impact on patients, while protecting those participating in the studies. This document provides guidance on the clinical development lifecycle, including designing quality into clinical studies, considering the broad range of clinical study designs and data sources used.
The ICH document "General Considerations for Clinical Studies" is intended to:
1. Describe internationally accepted principles and practices in the design and conduct of clinical studies that will ensure the protection of study participants and facilitate acceptance of data and results by regulatory authorities.
2. Provide guidance on the consideration of quality in the design and conduct of clinical studies across the product lifecycle, including the identification, during study planning, of factors that are critical to the quality of the study, and the management of risks to those factors during study conduct.
3. Provide an overview of the types of clinical studies performed during the product lifecycle, and describe study design elements that support the identification of quality factors critical to ensuring the protection of study participants, the integrity of the data, the reliability of results, and the ability of the studies to meet their objectives.
4. Provide a guide to the ICH efficacy documents to facilitate user's access.
This Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process. At Step 4 of the Process the final draft is recommended for adoption to the regulatory bodies of ICH regions.
Final version Adopted on 6 October 2021
Table of Contents
1. OBJECTIVES OF THIS DOCUMENT
2.1 Protection of Clinical Study Participants
2.2 Scientific Approach in Clinical Study Design, Planning, Conduct, Analysis, and
Reporting
2.3 Patient Input into Drug Development
3. DESIGNING QUALITY INTO CLINICAL STUDIES
3.1 Quality by Design of Clinical Studies
3.2 Critical to Quality Factors
3.3 Approach to Identifying the Critical to Quality Factors
3.3.1 Establishing a Culture that Supports Open Dialogue
3.3.2 Focusing on Activities Essential to the Study
3.3.3 Engaging Stakeholders in Study Design
3.3.4 Reviewing Critical to Quality Factors
3.3.5 Critical to Quality Factors in Operational Practice
4.1 Quality of Investigational Medicinal Product
4.2 Non-Clinical Studies
4.3 Clinical Studies
4.3.1 Human Pharmacology
4.3.2 Exploratory and Confirmatory Safety and Efficacy Studies
4.3.3 Special Populations
4.3.4 Post-Approval Studies
4.4 Additional Development
5. DESIGN ELEMENTS AND DATA SOURCES FOR CLINICAL STUDIES
5.1 Study Population
5.2 Treatment Description
5.3 Choice of Control Group
5.4 Response Variables
5.5 Methods to Reduce Bias
5.6 Statistical Analysis
5.7 Study Data
6. CONDUCT, SAFETY MONITORING, AND REPORTING
6.1 Study Conduct
6.1.1 Protocol Adherence
6.1.2 Training
6.1.3 Data Management
6.1.4 Access to Interim Data
6.2 Participant Safety during Study Conduct
6.2.1 Safety Monitoring
6.2.2 Withdrawal Criteria
6.2.3 Data Monitoring Committee
7. CONSIDERATIONS IN IDENTIFYING CRITICAL TO QUALITY FACTORS
ANNEX: TYPES OF CLINICAL STUDIES
Source: ICH Expert Working Group
Clinical Research News
Kommende kliniske studier
-
Antalya City HospitalHar ikke rekruttert ennåSmertebehandling | Pericapsular nervegruppeblokk (PENG-blokk) | Hofteproteser, totalt | Lateral femoral kutan nerveblokk | Quadro-Iliac Planblokk
-
Medipol UniversityHar ikke rekruttert ennå
-
Balikesir UniversityHar ikke rekruttert ennåLipødemTyrkia (Türkiye)
-
Aveta Biomics, Inc.Har ikke rekruttert ennåHode- og nakkekreft | Munnhulekarsinom | Orofarynx plateepitelkarsinom | Munnhule | Plateepitelkarsinom i munnhulen | Hode og nakke (HNSCC) | Oropharyngeal
-
The University of Texas Health Science Center at...Trauma Research and Combat Casualty Care Collaborative (TRC4)RekrutteringPosttraumatisk stresslidelse PTSDForente stater
-
Hoffmann-La RocheRekrutteringMultippel skleroseStorbritannia, Forente stater, Mexico, Brasil
-
Fred Hutchinson Cancer CenterArcus Biosciences, Inc.; Bench to Bedside (B2B)Har ikke rekruttert ennåMetastatisk nyrebekken Urothelial Carcinoma | Metastatisk Ureter Urothelial Carcinoma | Stadium IV blærekreft AJCC v8 | Stage IV nyrebekkenkreft AJCC v8 | Stage IV Ureterkreft AJCC v8 | Ikke-opererbart blære-urothelial karsinom | Ikke-opererbart nyrebekken Urothelial Carcinoma | Ikke-opererbart Ureter... og andre forholdForente stater
-
Intrinsic TherapeuticsHar ikke rekruttert ennåSkiveprolaps | Lumbar Disc Herniation SurgeryForente stater
-
Imam Abdulrahman Bin Faisal UniversityHar ikke rekruttert ennå
-
Gaziantep Islam Science and Technology UniversityThe Scientific and Technological Research Council of TurkeyHar ikke rekruttert ennåPostpartum Family Planning CounselingTyrkia (Türkiye)
-
Rebecca Ahrens-NicklasHar ikke rekruttert ennåUreasyklusforstyrrelser | Karbamoyl-fosfatsyntase I-mangelForente stater
-
National Cancer Institute (NCI)Har ikke rekruttert ennåHode- og nakkekreft | Nasofaryngealt karsinom | Hypopharyngeal kreft | Adenoid cystisk karsinom | Prostatakreft | Plateepitelkarsinom i hode og nakke | Orofaryngealt plateepitelkarsinom | Oral plateepitelkarsinom | Spyttkjertelkreft | Paranasale sinusneoplasmer | Metastatisk kastrasjonsresistent prostatakreft | Karsinom...Forente stater
Clinical Research Jobs
-
Japan - Tokyo
-
Singapore - Singapore
-
United States - Richmond
-
France - Ecully
-
United Kingdom - Leeds
-
Argentina - Buenos Aires
-
Romania - New York - Cluj-Napoca
-
India - Bengaluru
-
United States - North Carolina - Morrisville
-
China